TuHURA Biosciences (HURA) Research & Development (2012 - 2026)
TuHURA Biosciences (HURA) posted quarterly Research & Development of $5.2 million for Q1 2026, up 14.21% year-over-year from $4.6 million in Q1 2025, and down 13.59% quarter-over-quarter from $6.1 million in Q4 2025.
TuHURA Biosciences (HURA) Research & Development (2012 - 2026) Analysis & Trends
TuHURA Biosciences' Research & Development history runs 15 years deep, the most recent figure standing at $5.2 million for Q1 2026.
- In Q1 2026, Research & Development rose 14.21% year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $21.2 million (down 11.52% YoY), while the FY2025 annual figure was $20.5 million, up 53.97% from the prior year.
- Research & Development for Q1 2026 stood at $5.2 million, down from $6.1 million in the prior quarter.
- The five-year high for Research & Development was $9.4 million in Q3 2024, with the low at -$1.9 million in Q2 2023.
- The 5-year median for Research & Development is $3.6 million (2024), against an average of $3.9 million.
- The sharpest annual moves came in 2022 and 2024: Research & Development slumped 47.23% in 2022, then jumped 445.11% in 2024.
- TuHURA Biosciences' Research & Development stood at $2.1 million in 2022, then retreated by 4.32% to $2.0 million in 2023, then surged by 375.07% to $9.4 million in 2024, then tumbled by 35.3% to $6.1 million in 2025, then declined by 13.59% to $5.2 million in 2026.
- Business Quant data shows HURA's Research & Development at $5.2 million in Q1 2026, $6.1 million in Q4 2025, and $5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | TuHURA Biosciences | 37.61 Mn | 37.61 Mn | - | 6.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.23 Mn |
| Dec 31, 2025 | 6.06 Mn |
| Sep 30, 2025 | 4.97 Mn |
| Jun 30, 2025 | 4.93 Mn |
| Mar 31, 2025 | 4.58 Mn |
| Sep 30, 2024 | 9.36 Mn |
| Jun 30, 2024 | 6.41 Mn |
| Mar 31, 2024 | 3.59 Mn |
| Dec 31, 2023 | 1.97 Mn |
| Sep 30, 2023 | 1.86 Mn |
| Jun 30, 2023 | -1.86 Mn |
| Mar 31, 2023 | 2.01 Mn |
| Dec 31, 2022 | 2.06 Mn |
| Sep 30, 2022 | 3.17 Mn |
| Mar 31, 2022 | 3.47 Mn |
| Dec 31, 2021 | 3.90 Mn |
| Sep 30, 2021 | 3.79 Mn |
| Jun 30, 2021 | 4.03 Mn |
| Mar 31, 2021 | 3.84 Mn |
| Dec 31, 2020 | 2.58 Mn |